Physician

Benjamin B Bridges, MD

According to 2025 Medicare claims, Benjamin Bridges, MD (NPI: 1477694420) practices hematology/oncology in the Baltimore-Columbia-Towson, MD market, with the plurality of this provider's patient population coming from Anne Arundel, MD. This provider's primary affiliated billing organization is MARYLAND ONCOLOGY HEMATOLOGY P.A. (NPI: 1396710703; TIN: 113652573) and primary practice location at 21401-9998. Bridges is affiliated with the Aledade 61 WA CCCN CHC MSSP Enhanced (ACO ID: A4777), participating under the MSSP model.

Bridges' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,406 traditional Medicare patients, billed 163,447 HCPCS/CPT codes, and received $3,284,239 in Medicare payments. The top billing code was 82728 (Ferritin (blood protein) level). Part D data shows 1,148 prescription claims across 158 beneficiaries totaling $3,037,170 in drug costs, led by Calquence (Acalabrutinib Maleate). DME data shows 64 claims. Open Payments data shows 75 records totaling $4,998. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $60,861 to $3,284,239. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,099,573 and ending at $3,037,170. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,819 and ending at $1,327.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	307	1,254	$60,861
2016	328	1,190	$58,974
2017	323	895	$41,912
2018	334	967	$46,254
2019	325	848	$54,213
2020	314	21,466	$648,357
2021	122	4,945	$107,115
2022	286	11,838	$277,924
2023	1,456	88,053	$1,529,398
2024	2,406	163,447	$3,284,239

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	178	1,297	$1,099,573
2016	199	1,324	$1,454,827
2017	193	1,224	$2,040,147
2018	194	1,191	$2,226,973
2019	183	655	$822,126
2020	96	520	$227,179
2021	47	234	$255,729
2022	86	440	$1,051,508
2023	114	687	$1,546,597
2024	158	1,148	$3,037,170

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	128	$31,238
2016	N/R	18	$1,137
2017	N/R	14	$787
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	107	$9,274
2021	N/R	N/R	N/R
2022	N/R	31	$1,697
2023	N/R	97	$10,403
2024	N/R	64	$1,219

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
82728	Ferritin (blood protein) level	706	1,400	$13
80053	Blood test, comprehensive group of blood chemicals	1,690	6,403	$10
83550	Iron binding capacity	692	1,334	$9
83540	Iron level	687	1,327	$6
83615	Lactate dehydrogenase (enzyme) level	513	1,035	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	24	720	$363,265
Brukinsa	Zanubrutinib	16	480	$240,820
Verzenio	Abemaciclib	16	448	$234,629
Revlimid	Lenalidomide	14	364	$220,940
Abiraterone Acetate	Abiraterone Acetate	23	690	$208,376

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	20	$573
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	24	$433
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	20	$213

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	72	$1,976	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$3,022	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Benjamin B. Bridges, MD?

Tedicare shows public-source Medicare data for Benjamin B. Bridges, MD (NPI 1477694420), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Benjamin B. Bridges, MD have ACO affiliation data?

Benjamin B. Bridges, MD is shown with ACO affiliation data for Aledade 61 WA CCCN CHC MSSP Enhanced (MSSP, ACO ID A4777).

What billing organization is linked to Benjamin B. Bridges, MD?

Benjamin B. Bridges, MD is linked to MARYLAND ONCOLOGY HEMATOLOGY P.A. (billing NPI 1396710703) in the available physician profile data.

Does Benjamin B. Bridges, MD have Open Payments data?

Benjamin B. Bridges, MD has 75 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.